Evidence map›Paper›PMID 36416944›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2023

A common variant close to the "tripwire" linker region of NLRP1 contributes to severe COVID-19.

Vinicius N C Leal, Leandro M Paulino, Raylane A G Cambui, Thiago G Zupelli, Suemy M Yamada, Leonardo A T Oliveira, Valéria de F Dutra, Carolina B Bub, Araci M Sakashita, Ana Paula H Yokoyama and 13 more

Open access · bronzeAbstract read
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. GenoDense-Net: unraveling the genomic puzzle of the global pathogen.Tropical diseases, travel medicine and vaccines · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 2 countries.

Vinicius N C LealLaboratório de Imunogenética, Departamento de Imunologia, Instituto de Ciências Biomédicas/ICB, Universidade de São Paulo/USP, São Paulo, SP, Brasil.
Leandro M PaulinoFaculdade de Medicina, Universidade Federal de Mato Grosso do Sul, Campo grande, Mato Grosso do Sul, Brasil.
Raylane A G CambuiLaboratório de Imunogenética, Departamento de Imunologia, Instituto de Ciências Biomédicas/ICB, Universidade de São Paulo/USP, São Paulo, SP, Brasil.
Thiago G ZupelliLaboratório de Imunogenética, Departamento de Imunologia, Instituto de Ciências Biomédicas/ICB, Universidade de São Paulo/USP, São Paulo, SP, Brasil.
Suemy M YamadaLaboratório de Imunogenética, Departamento de Imunologia, Instituto de Ciências Biomédicas/ICB, Universidade de São Paulo/USP, São Paulo, SP, Brasil.
Leonardo A T OliveiraLaboratório de Imunogenética, Departamento de Imunologia, Instituto de Ciências Biomédicas/ICB, Universidade de São Paulo/USP, São Paulo, SP, Brasil.
Valéria de F DutraDepartamento de Hemoterapia, Hospital Israelita Albert Einstein, São Paulo, SP, Brasil.
Carolina B BubDepartamento de Hemoterapia, Hospital Israelita Albert Einstein, São Paulo, SP, Brasil.
Araci M SakashitaDepartamento de Hemoterapia, Hospital Israelita Albert Einstein, São Paulo, SP, Brasil.
Ana Paula H YokoyamaDepartamento de Hemoterapia, Hospital Israelita Albert Einstein, São Paulo, SP, Brasil.
José M KutnerDepartamento de Hemoterapia, Hospital Israelita Albert Einstein, São Paulo, SP, Brasil.
Camila A VieiraFaculdade de Medicina, Universidade Federal de Mato Grosso do Sul, Campo grande, Mato Grosso do Sul, Brasil.
Wellyngton M de S SantiagoFaculdade de Medicina, Universidade Federal de Mato Grosso do Sul, Campo grande, Mato Grosso do Sul, Brasil.
Milena M S AndradeLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM-56, Departamento de Dermatologia, Hospital das Clínicas E Faculdade de Medicina/HCFMUSP, São Paulo, Brasil.
Franciane M E TeixeiraLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM-56, Departamento de Dermatologia, Hospital das Clínicas E Faculdade de Medicina/HCFMUSP, São Paulo, Brasil.
Ricardo W AlbercaLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM-56, Departamento de Dermatologia, Hospital das Clínicas E Faculdade de Medicina/HCFMUSP, São Paulo, Brasil.
Sarah C Gozzi-SilvaLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM-56, Departamento de Dermatologia, Hospital das Clínicas E Faculdade de Medicina/HCFMUSP, São Paulo, Brasil.
Tatiana M YendoDepartamento de Dermatologia, Faculdade de Medicina, Instituto de Medicina Tropical, Universidade de São Paulo/FMUSP, São Paulo, Brasil.
Lucas C NettoUnidade Terapia Intensiva, Hospital das Clínicas/FMUSP, São Paulo, Brasil.
Alberto J S DuarteLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM-56, Departamento de Dermatologia, Hospital das Clínicas E Faculdade de Medicina/HCFMUSP, São Paulo, Brasil.
Maria N SatoLaboratório de Investigação Médica em Dermatologia e Imunodeficiências (LIM-56, Departamento de Dermatologia, Hospital das Clínicas E Faculdade de Medicina/HCFMUSP, São Paulo, Brasil.
James VenturiniFaculdade de Medicina, Universidade Federal de Mato Grosso do Sul, Campo grande, Mato Grosso do Sul, Brasil.
Alessandra PontilloLaboratório de Imunogenética, Departamento de Imunologia, Instituto de Ciências Biomédicas/ICB, Universidade de São Paulo/USP, São Paulo, SP, Brasil. alepontillo@usp.br.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo · BRHospital Israelita Albert Einstein · BRInstituto de Medicina Tropical · PYUniversidade Federal de Mato Grosso do Sul · BRUniversidade de São Paulo · BR

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 88887.503842/2020-00Fundação de Amparo à Pesquisa do Estado de São Paulo 2021/05420-4Ministero da Educaçao TED SESU/MEC 9233/2020
6 · The paper itself

Abstract

OBJECTIVE AND

designThe heterogeneity of response to SARS-CoV-2 infection is directly linked to the individual genetic background. Genetic variants of inflammasome-related genes have been pointed as risk factors for several inflammatory sterile and infectious disease. In the group of inflammasome receptors, NLRP1 stands out as a good novel candidate as severity factor for COVID-19 disease.

methodsTo address this question, we performed an association study of NLRP1, DPP9, CARD8, IL1B, and IL18 single nucleotide variants (SNVs) in a cohort of 945 COVID-19 patients.

resultsThe NLRP1 p.Leu155His in the linker region, target of viral protease, was significantly associated to COVID-19 severity, which could contribute to the excessive cytokine release reported in severe cases.

conclusionInflammasome genetic background contributes to individual response to SARS-CoV-2.

Indexed as

COVID-19InflammasomesAdaptor Proteins, Signal TransducingCARD Signaling Adaptor ProteinsHumansNeoplasm ProteinsNLR ProteinsSARS-CoV-2Adaptor Proteins, Signal TransducingCARD8 protein, humanCARD Signaling Adaptor ProteinsInflammasomesNeoplasm ProteinsNLRP1 protein, humanNLR ProteinsCOVID-19InflammasomeNLRP1SARS-CoV-2SNV

Identifiers

PMID36416944
PMCPMC9684769
OpenAlexW4309822782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.